Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials
- 30 September 2021
- journal article
- review article
- Published by Elsevier BV in Endocrine Practice
- Vol. 28 (2), 223-230
- https://doi.org/10.1016/j.eprac.2021.09.013
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetesDiabetes/Metabolism Research and Reviews, 2014
- Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?BMC Medical Research Methodology, 2014
- Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)Digestive Diseases and Sciences, 2013
- Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver diseaseJournal of Hepatology, 2011
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJournal of Clinical Epidemiology, 2011
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Barriers to regular exercise among adults at high risk or diagnosed with type 2 diabetes: a systematic reviewHealth Promotion International, 2009
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionJournal of Hepatology, 2006
- Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight lossJournal of Hepatology, 2004